Effects of compound xuanju capsule on T lymphocyte subsets in patients with unexplained recurrent abortion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042007

Enrollment

Unknown

Registered

2021-01-12

Start date

2016-02-01

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent abortion

Interventions

URSA Group:Compound xuanju capsule therapy

normal non-pregnant women group:empty

Eligibility

Sex/Gender

Female

Age

26 Years to 37 Years

Inclusion criteria

Inclusion criteria: 1. Patients with definite diagnosis of URSA; 2. Patients older than 18 years; 3. Patients who have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe infection; 2. Patients with severe heart, liver and kidney dysfunction; 3. Patients with advanced malignant tumors; 4. Patients with incomplete case data.

Design outcomes

Primary

Measure	Time frame
T lymphocyte subsets;T lymphocyte subsets;T lymphocyte subsets;T lymphocyte subsets;	—

Countries

China

Contacts

Public ContactKang Yu

Weifang People's Hospital

happyyukang@126.com+86 13864660073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026